$RGLS
Regulus Therapeutics Inc.

2013 Q2 Form 10-Q Financial Statement

#000119312513333123 Filed on August 14, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2012 Q2
Revenue $4.759M $3.309M
YoY Change 43.82% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.720M $980.0K
YoY Change 75.51%
% of Gross Profit
Research & Development $7.722M $4.883M
YoY Change 58.14%
% of Gross Profit
Depreciation & Amortization $340.0K $250.0K
YoY Change 36.0% -41.86%
% of Gross Profit
Operating Expenses $9.445M $5.867M
YoY Change 60.99% 7.73%
Operating Profit -$4.686M -$2.558M
YoY Change 83.19%
Interest Expense $18.00K $90.00K
YoY Change -80.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$7.338M -$2.621M
YoY Change 179.97%
Income Tax $10.00K -$22.00K
% Of Pretax Income
Net Earnings -$7.348M -$2.599M
YoY Change 182.72% 15.36%
Net Earnings / Revenue -154.4% -78.54%
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share -$0.20 -$130.0M
COMMON SHARES
Basic Shares Outstanding 35.99M shares
Diluted Shares Outstanding 35.99M shares

Balance Sheet

Concept 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $82.70M $27.00M
YoY Change 206.3%
Cash & Equivalents $19.17M $4.928M
Short-Term Investments $63.50M $22.10M
Other Short-Term Assets $1.600M $600.0K
YoY Change 166.67%
Inventory
Prepaid Expenses
Receivables $2.500M
Other Receivables $0.00
Total Short-Term Assets $86.87M $27.60M
YoY Change 214.76%
LONG-TERM ASSETS
Property, Plant & Equipment $4.011M $3.400M
YoY Change 17.97%
Goodwill
YoY Change
Intangibles $1.229M
YoY Change
Long-Term Investments
YoY Change
Other Assets $404.0K $1.100M
YoY Change -63.27%
Total Long-Term Assets $5.644M $5.600M
YoY Change 0.79%
TOTAL ASSETS
Total Short-Term Assets $86.87M $27.60M
Total Long-Term Assets $5.644M $5.600M
Total Assets $92.52M $33.20M
YoY Change 178.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.028M $800.0K
YoY Change 28.5%
Accrued Expenses $2.081M $3.300M
YoY Change -36.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $10.20M
YoY Change
Total Short-Term Liabilities $19.01M $22.50M
YoY Change -15.53%
LONG-TERM LIABILITIES
Long-Term Debt $14.60M $400.0K
YoY Change 3550.0%
Other Long-Term Liabilities $1.765M $13.50M
YoY Change -86.93%
Total Long-Term Liabilities $1.765M $13.90M
YoY Change -87.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.01M $22.50M
Total Long-Term Liabilities $1.765M $13.90M
Total Liabilities $43.20M $36.50M
YoY Change 18.35%
SHAREHOLDERS EQUITY
Retained Earnings -$75.00M
YoY Change
Common Stock $36.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.32M -$3.300M
YoY Change
Total Liabilities & Shareholders Equity $92.52M $33.20M
YoY Change 178.67%

Cashflow Statement

Concept 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$7.348M -$2.599M
YoY Change 182.72% 15.36%
Depreciation, Depletion And Amortization $340.0K $250.0K
YoY Change 36.0% -41.86%
Cash From Operating Activities -$7.430M -$4.670M
YoY Change 59.1% -59.14%
INVESTING ACTIVITIES
Capital Expenditures -$190.0K -$380.0K
YoY Change -50.0% 58.33%
Acquisitions
YoY Change
Other Investing Activities $8.910M $100.0K
YoY Change 8810.0% -98.17%
Cash From Investing Activities $8.720M -$280.0K
YoY Change -3214.29% -105.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 60.00K -220.0K
YoY Change -127.27% 29.41%
NET CHANGE
Cash From Operating Activities -7.430M -4.670M
Cash From Investing Activities 8.720M -280.0K
Cash From Financing Activities 60.00K -220.0K
Net Change In Cash 1.350M -5.170M
YoY Change -126.11% -18.97%
FREE CASH FLOW
Cash From Operating Activities -$7.430M -$4.670M
Capital Expenditures -$190.0K -$380.0K
Free Cash Flow -$7.240M -$4.290M
YoY Change 68.76% -61.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
5000000
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36155745 shares
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4928000
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1620000
CY2013Q2 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
81946000
CY2013Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
404000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
49321000
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2013Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
4.00
CY2013Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1020000
CY2013Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
82715000
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36081615 shares
CY2013Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
2538000
CY2013Q2 us-gaap Liabilities
Liabilities
43196000
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1028000
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14876000
CY2013Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1765000
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-74996000
CY2013Q2 us-gaap Assets
Assets
92517000
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.53
CY2013Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
5400000
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92517000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19170000
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36081615 shares
CY2013Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1229000
CY2013Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-82000
CY2013Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8689152 shares
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2081000
CY2013Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3109000
CY2013Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
14592000
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
19005000
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4647000 shares
CY2013Q2 us-gaap Short Term Investments
ShortTermInvestments
63545000
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
36000
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7834000
CY2013Q2 us-gaap Assets Current
AssetsCurrent
86873000
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4011000
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
124363000
CY2013Q2 rgls Short Term Investments Amortized Cost
ShortTermInvestmentsAmortizedCost
63617000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9175000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
829000
CY2012Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
96911000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
125000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
62093000
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1348000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35831808 shares
CY2012Q4 us-gaap Liabilities
Liabilities
41425000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
311000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10451000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
767000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60419000
CY2012Q4 us-gaap Assets
Assets
103518000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.11
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103518000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40552000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35831808 shares
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1154000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-52000
CY2012Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7124739 shares
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
658000
CY2012Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
10134000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12768000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4720000 shares
CY2012Q4 us-gaap Short Term Investments
ShortTermInvestments
57548000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
17756000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
98929000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3310000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
122528000
CY2012Q4 rgls Short Term Investments Amortized Cost
ShortTermInvestmentsAmortizedCost
57590000
dei Trading Symbol
TradingSymbol
RGLS
dei Entity Registrant Name
EntityRegistrantName
REGULUS THERAPEUTICS INC.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001505512
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
1055000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10235000
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Deferred Revenue</i></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying condensed balance sheets. Amounts not expected to be recognized within the next 12 months are classified as non-current deferred revenue.</font></p> </div>
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
717000
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0049 pure
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
289000
us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
2950000
us-gaap Fair Value Assumptions Weighted Average Volatility Rate
FairValueAssumptionsWeightedAverageVolatilityRate
0.70 pure
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-9000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14606000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1025000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
629000
us-gaap Share Based Compensation
ShareBasedCompensation
1546000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.81
us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
74000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.33
us-gaap Profit Loss
ProfitLoss
-14577000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7028000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
223000 shares
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1256232 shares
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
56000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14587000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-7997000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.91
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-4458000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
268000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-21382000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-327000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3628000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
850000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
45853000
us-gaap Interest And Other Income
InterestAndOtherIncome
135000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14604000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
233000
us-gaap Operating Expenses
OperatingExpenses
18232000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
190000 shares
us-gaap Revenues
Revenues
7997000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1546000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14576000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-638000
us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
2000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
39000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
96000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35933961000 shares
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-10000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3929209 shares
us-gaap Net Income Loss
NetIncomeLoss
-14577000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
340000 shares
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
5000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
19984000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Our financial statements are prepared in accordance with GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</font></p> </div>
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
13320000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-29000
us-gaap Fair Value Inputs Entity Credit Risk
FairValueInputsEntityCreditRisk
0.088 pure
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
160000
us-gaap Interest Expense
InterestExpense
18000
rgls Amounts Accrued For Patent Expenditures
AmountsAccruedForPatentExpenditures
19000
rgls Payments For Deferred Offering Costs
PaymentsForDeferredOfferingCosts
360000
rgls Proceeds From Issuance Initial Public Offering Gross
ProceedsFromIssuanceInitialPublicOfferingGross
49163000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
209000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4739000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
260000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4813000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
29000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
481000
us-gaap Share Based Compensation
ShareBasedCompensation
318000
us-gaap Profit Loss
ProfitLoss
-4847000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-23.46
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
216000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9797000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5842000
us-gaap Income Taxes Paid
IncomeTaxesPaid
206000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6467000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
734000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4247000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
117000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1905000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
64000
us-gaap Interest And Other Income
InterestAndOtherIncome
54000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9487000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-292000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
206610000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16234149 shares
us-gaap Operating Expenses
OperatingExpenses
11392000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
110000
us-gaap Revenues
Revenues
6653000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
318000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4869000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-233000
us-gaap Interest Paid
InterestPaid
22000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
130000
us-gaap Net Income Loss
NetIncomeLoss
-4847000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-22000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
7075000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
13781000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
34000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-37000
us-gaap Interest Expense
InterestExpense
184000
rgls Amounts Accrued For Patent Expenditures
AmountsAccruedForPatentExpenditures
30000
CY2012 us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
49000
CY2012 us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
7000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2558000
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2631000
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.78
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
984000
CY2012Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
27000
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4883000
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
5867000
CY2012Q2 us-gaap Revenues
Revenues
3309000
CY2012Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
205000
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2621000
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
241223000 shares
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16131655 shares
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-2599000
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-22000
CY2012Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-32000
CY2012Q2 us-gaap Interest Expense
InterestExpense
90000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4686000
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7392000
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2013Q2 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-2697000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1723000
CY2013Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
63000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7722000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
9445000
CY2013Q2 us-gaap Revenues
Revenues
4759000
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4257789 shares
CY2013Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
759000
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7338000
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35994642000 shares
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10000
CY2013Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-44000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-7348000
CY2013Q2 us-gaap Interest Expense
InterestExpense
18000

Files In Submission

Name View Source Status
0001193125-13-333123-index-headers.html Edgar Link pending
0001193125-13-333123-index.html Edgar Link pending
0001193125-13-333123.txt Edgar Link pending
0001193125-13-333123-xbrl.zip Edgar Link pending
d556172d10q.htm Edgar Link pending
d556172dex311.htm Edgar Link pending
d556172dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R37.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R38.xml Edgar Link unprocessable
R39.htm Edgar Link pending
R39.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
rgls-20130630.xml Edgar Link completed
rgls-20130630.xsd Edgar Link pending
rgls-20130630_cal.xml Edgar Link unprocessable
rgls-20130630_def.xml Edgar Link unprocessable
rgls-20130630_lab.xml Edgar Link unprocessable
rgls-20130630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending